Form 4: Voyager Therapeutics Director Catherine Mackey Receives New Stock Option Grant

Voyager Therapeutics, Inc. director Catherine J. Mackey was granted 24,000 stock options with an exercise price of $3.28, vesting upon the earlier of one year or the next annual meeting, as part of the company's 2025 Stock Incentive Plan.

Summary

• Catherine J. Mackey, a Director of Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options.
• The transaction date for this grant was June 3, 2025.
• Each stock option has an exercise price of $3.28.
• The options are exercisable immediately upon grant and have an expiration date of June 3, 2035.
• The underlying securities for these options are 24,000 shares of Common Stock.
• This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. and is in accordance with its director compensation policy.
• The options vest upon the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date of the next annual meeting of stockholders, subject to Ms. Mackey's continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a standard and expected compensation event that aligns the interests of a director with the company's shareholders, which is generally viewed favorably. It is not a major market-moving event but reflects sound corporate governance practices.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• This action is consistent with the company's established director compensation policy, indicating adherence to corporate governance frameworks.

Future Outlook

The vesting schedule of the options, tied to continued service, implies an expectation of Catherine J. Mackey's ongoing commitment and contribution as a director to Voyager Therapeutics.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology, serving as a key component of compensation packages designed to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Sarepta Therapeutics, Inc., which frequently use equity-based incentives to align director and executive interests with shareholder value.
• The vesting terms, tied to continued service over one year or until the next annual meeting, are typical for director equity grants, ensuring ongoing commitment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Catherine J. Mackey, a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact mentioned, but consistent compensation practices can contribute to overall company stability and morale.

Next Steps

• Catherine J. Mackey's continued service as a director is required for the vesting of the granted stock options.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals